MRNA Synthesis Service - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the mRNA synthesis service market size is expected to increase from USD 6.80 billion in 2025 to USD 7.31 billion in 2026 and reach USD 10.55 billion by 2031, growing at a CAGR of 7.60% over 2026-2031.

This report is Segmented by Service Type (Custom MRNA Synthesis, GMP-Grade Manufacturing, and More), Scale (Research Grade, Pre-Clinical Grade, and More), Application (Vaccines, Oncology Therapeutics, and More), End-User (Biotechnology and Pharmaceutical Companies, and More), and Geography (North America, Europe, Asia Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global MRNA Synthesis Service Market Trends and Insights

Post-COVID Vaccine Pipeline Expansion Drives Therapeutic Diversification

The proven success of nucleoside-modified COVID-19 vaccines turns the spotlight on oncology, RSV, and rare-disease programs now advancing toward approval. Moderna is running as many as 10 late-stage candidates, including personalized cancer vaccines, RSV prophylactics, and a combined influenza/COVID-19 shot. Positive data on mRNA-4157 with pembrolizumab showed a 44% reduction in melanoma recurrence, validating the platform for immuno-oncology. CDMOs answer by installing dedicated suites for high-potency and personalized batches; TriLink BioTechnologies recently opened a large-scale cGMP line for late-phase drug-substance production.

Outsourcing Boom Transforms CDMO Competitive Dynamics

Big pharma is scaling back internal capacity as biological complexity and capital intensity soar. Pfizer's multi-year program targets USD 1.5 billion in manufacturing savings, reallocating funds to clinical assets while partnering with external experts. Recent deals-Agilent acquiring BIOVECTRA for USD 925 million and Maravai LifeSciences purchasing Officinae Bio's nucleic-acid unit-illustrate consolidation around end-to-end mRNA capabilities.

GMP Compliance and Validation Bottlenecks Constrain Scale-Up

Revised EMA guidelines for ATMPs and new USP chapters on mRNA vaccines tighten release criteria, mandating advanced analytics such as next-generation sequencing and orthogonal purity assays. The FDA's Advanced Manufacturing Technologies Framework now requires extensive documentation for novel processes. CDMOs invest in automated quality systems and digital batch records; Moderna cut R&D spend by USD 1.1 billion through process-validation efficiencies.

Other drivers and restraints analyzed in the detailed report include:

1. High-Efficiency IVT and Capping Innovations Reduce Manufacturing Bottlenecks
2. Venture and Government Funding Influx Accelerates Capacity Expansion
3. Supply-Chain Crunch for High-Purity Reagents Creates Cost Pressures

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

GMP-grade manufacturing retained the largest share at 46.4% in 2025, reflecting its entrenched infrastructure and regulators' preference for validated platforms. At the same time, custom synthesis is advancing at a 9.1% CAGR, fueled by demand for individualized cancer vaccines and rare-disease therapies. CDMOs embed AI tools to rapidly iterate sequence constructs, enabling clients to progress from design to IND in under six months. Design-optimization and analytical suites are now standard, as illustrated by the AmplifyBio-RNAV8 collaboration that bundles sequence design, IVT, LNP formulation, and release testing under one roof. The mRNA synthesis services market size for bespoke projects is expected to grow as pay-for-performance models become more prevalent. Intellectual property advantages-such as TriLink's CleanCap and Aldevron's high-fidelity plasmids-create durable moats and enable premium pricing.

The widening of service menus mirrors the overall maturation of the mRNA synthesis services market. Raw-material supply agreements safeguard enzyme and nucleotide availability, while hybrid fee structures (capacity reservation plus per-batch charges) help CDMOs offset macroeconomic volatility. As clients aim for accelerated approval pathways, providers integrate regulatory-affairs consulting and companion-diagnostics development, further embedding themselves in sponsor workflows.

Clinical GMP batches account for 38.9% of revenue, covering pivotal trials and early launches. The mRNA synthesis services market share for modular facilities, however, is expanding quickest at an 8.4% CAGR. Containerized cleanrooms can be fitted onto a single truck, require minimal civil works, and can transition between 50 mg preclinical runs and multi-kilogram commercial lots within days. BioNTech estimates that a two-unit BioNTainer can deliver 50 million doses annually, with 70% lower capital expenditure (capex) than a traditional plant. For more minor indications, continuous-flow micro-reactors produce on-demand lots, reducing inventory costs.

Legacy commercial-scale suites are consolidating around the use of multiple products. Lonza's acquisition of Roche's Vacaville plant added 330,000 L mammalian capacity, now partially retrofitted for mRNA LNP finishing, exemplifying asset repurposing to balance pipeline uncertainty. Hybrid models-central bulk RNA followed by regional fill-finish-enhance resilience to supply-chain shocks.

Geography Analysis

North America controlled 42.4% of revenue in 2025, anchored by a deep talent pool, robust IP protection, and aggressive public-private funding. Three Moderna plants set to go live in 2025-Canada, the U.K., and Australia-will each turn out up to 100 million doses annually, reinforcing cross-regional supply chains while retaining critical steps in the U.S.. The U.S. Biomedical Advanced Research and Development Authority (BARDA) continues to issue multi-year "warm-base" contracts guaranteeing surge capacity.

Europe benefits from cohesive regulatory frameworks and strategic manufacturing hubs. Wacker's USD 102 million competence center in Germany adds four RNA lines, half reserved for federal pandemic stockpiles. The European Pharmacopoeia's new general chapter on mRNA quality sets reference standards that streamline batch release across member states.

Asia-Pacific is the fastest-growing region at a 6.4% CAGR. China's WuXi Biologics and GenScript expansions, South Korea's Moderna partnership, and Singapore's role as BioNTech's ASEAN headquarters illustrate concerted sovereign strategies. Australia's Aurora Biosynthetics targets end-to-end GMP from plasmid to fill-finish, leveraging USD 200 million in federal backing. Taiwan Bio-Manufacturing Corp aims to replicate the semiconductor foundry model for biopharma, signaling long-term regional ambition.

Middle East & Africa tap into modular systems to bridge infrastructure gaps. HT-Bio's deployment of KeyPlants PODs in Saudi Arabia marks early adoption. South America expands through tech-transfer agreements in Brazil and Argentina, improving regional vaccine autonomy.

1. TriLink BioTechnologies
2. Aldevron (Danaher)
3. Thermo Fisher Scientific (Patheon)
4. Lonza Group
5. Catalent
6. Samsung Group
7. AGC Biologics
8. Wuxi Biologics
9. Moderna
10. BioNTech
11. CureVac
12. New England Biolabs
13. Genscript
14. Creative Biolabs
15. BOC RNA (BOC Sciences)
16. Cellerna Bioscience
17. eTheRNA Manufacturing
18. Kactus Biosystems
19. Acuitas Therapeutics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support